Organon & Co
XBER:7XP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Organon & Co
XBER:7XP
|
US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
US |
|
G
|
GeeCee Ventures Ltd
NSE:GEECEE
|
IN |
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
JP |
|
Equinox Gold Corp
TSX:EQX
|
CA |
|
Electrocomponents PLC
F:ECN
|
UK |
|
Veritone Inc
NASDAQ:VERI
|
US |
|
Apollo Medical Holdings Inc
NASDAQ:ASTH
|
US |
|
HIAG Immobilien Holding AG
SIX:HIAG
|
CH |
|
PSP Projects Ltd
NSE:PSPPROJECT
|
IN |
|
Express Inc
OTC:EXPRQ
|
US |
Wall St Price Targets
7XP Price Targets Summary
Organon & Co
According to Wall Street analysts, the average 1-year price target for 7XP is 7.747 EUR with a low forecast of 5.682 EUR and a high forecast of 10.337 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 7XP's stock price target?
Price Target
7.747
EUR
According to Wall Street analysts, the average 1-year price target for 7XP is 7.747 EUR with a low forecast of 5.682 EUR and a high forecast of 10.337 EUR.
What is the Revenue forecast for Organon & Co?
Projected CAGR
0%
Over the last 7 years, the compound annual growth rate for Revenue has been -6%. The projected CAGR for the next 7 years is 0%.
What is the Operating Income forecast for Organon & Co?
Projected CAGR
4%
Over the last 7 years, the compound annual growth rate for Operating Income has been -10%. The projected CAGR for the next 7 years is 4%.
What is the Net Income forecast for Organon & Co?
Projected CAGR
26%
Over the last 7 years, the compound annual growth rate for Net Income has been -29%. The projected CAGR for the next 7 years is 26%.
